Invasive fungal infections in lung transplantation: role of aerosolised amphotericin B

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 2, 2008, Pages

  Solé, Amparo ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Aerosolised; Amphotericin B; Lung transplantation

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CORTICOSTEROID; FLUCONAZOLE; PLACEBO;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; ASPIRATION PNEUMONIA; BRONCHUS HYPERREACTIVITY; CANCER PATIENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAFT RECIPIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; LUNG LAVAGE; LUNG TRANSPLANTATION; MYCOSIS; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHEMOPREVENTION; HUMANS; LUNG DISEASES, FUNGAL; LUNG TRANSPLANTATION;

EID: 55649118858     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(08)70019-0     Document Type: Article

References (31)

1. Kotloff R.M., Ahya V.N., and Crawford S.W. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 170 (2004) 22-48
2. Fridkin S.K. The changing face of fungal infections in health care settings. Clin Infect Dis 41 (2005) 1455-1460
3. Marr K.A., Carter R.A., Boeckh M., Martin P., and Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100 (2002) 4358-4366
4. Marik P.E. Fungal infections in solid organ transplantation. Expert Opin Pharmacother 7 (2006) 297-305
5. Bow E.J. Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients. Med Mycol 43 Suppl 1 (2005) S277-S287
6. Singh N., and Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 22 (2003) 258-266
7. Solé A., Morant P., Salavert M., Pemán J., Morales P., and Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 11 (2005) 359-365
8. Magill S.S. Antifungal prophylaxis in transplant recipients: where do we go from here?. Transpl Infect Dis 8 (2006) 187-189
9. Drew R. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. Int J Antimicrob Agents 27 Suppl 1 (2006) 36-44
10. Husain S., Zaldonis D., Kusne S., et al. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 8 (2006) 213-218
11. Covarrubias M.B., and Milstone A.B. An overview of fungal prophylaxis in lung transplantation. Curr Opin Organ Transplant 10 (2005) 227-232
12. Hagerman J.K., Hancock K.E., and Klepser M.E. Aerosolised antibiotics: a critical appraisal of their use. Expert Opin Drug Deliv 3 (2006) 71-86
13. Corcoran T.E., Venkataramanan R., Mihel K.M., et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 6 (2006) 2765-2773
14. Monforte V., Roman A., Gavalda J., et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 20 (2001) 1274-1281
15. Monforte V., Roman A., Gavalda J., et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 75 (2003) 1571-1574
16. Singh N., Pruett T.L., Houston S., et al. Invasive aspergillosis in the recipients of liver retransplantation. Liver Transpl 12 (2006) 1205-1209
17. Fortun J., Martín-Davila P., Moreno S., et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 52 (2003) 813-819
18. Allen S.D., Sorensen K.N., Nejdl M.J., Durrant C., and Proffit R.T. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 34 (1994) 1001-1013
19. Cicogna C.E., White M.H., Bernard E.M., et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 41 (1997) 259-261
20. Palmer S.M., Drew R.H., Whitehouse J.D., et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 72 (2001) 545-548
21. Drew R.H., Dodds A.E., Benjamin Jr. D.K., et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 77 (2004) 232-237
22. Borro JM, Solé A, de la Torre M. Efficiency and safety of inhaled amphotericin B complex (Abelcet®) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc. Forthcoming.
23. Alexander B.D. Non comparative evaluation of the safety of aerosolized B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 8 (2006) 13-20
24. Ruiz I, Molina I, Gavalda J, et al. Safety and tolerability of nebulized liposomal amphotericin B in haematologic patients. In: Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 16-19 December 2005; Washington, DC. Washington, DC: ASM Press; 2005. Abstract M-977.
25. Monforte V., Roman A., Gavalda J., et al. Nebulized liposomal amphotericin B (n-LAB) prophylaxis for Aspergillus infection in lung transplantation (LT): pharmacokinetics, safety and efficacy. J Heart Lung Transplant 24 (2005) S108-S109
26. Lowry C.M., Marty F.M., Vargas S.O., et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transplant Infect Dis 9 (2007) 121-125
27. Calvo V., Borro J.M., Morales P., et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Chest 115 (1999) 1301-1304
28. Gallagher J, Ashley E, Howell D, Palmer S, Perfect J, Drew R. Foamy macrophages in bronchoalveolar lavage fluid from lung transplant recipients receiving aerosolized formulations of amphotericin B. In: Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 30 October-2 November 2004; Washington, DC. Washington, DC: ASM Press; 2004. Abstract M-1977.
29. Singh N., Limaye A., Forrest G., et al. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Med Mycol 44 (2006) 445-449
30. San Juan Garrido R., Aguado J.M., Díaz-Pedroche C., et al. A review of critical periods for opportunistic infection in the new transplantation era. Transplantation 82 (2006) 1457-1462
31. San Juan Garrido R., Aguado J.M., Lumbreras C., et al. RESITRA Network, Spain Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from RESITRA study group. Am J Transplant 7 (2007) 964-971